[go: up one dir, main page]

DE69120500D1 - Azasteroide zur Behandlung prostatischer Hypertrophie, ihre Herstellung und Verwendung - Google Patents

Azasteroide zur Behandlung prostatischer Hypertrophie, ihre Herstellung und Verwendung

Info

Publication number
DE69120500D1
DE69120500D1 DE69120500T DE69120500T DE69120500D1 DE 69120500 D1 DE69120500 D1 DE 69120500D1 DE 69120500 T DE69120500 T DE 69120500T DE 69120500 T DE69120500 T DE 69120500T DE 69120500 D1 DE69120500 D1 DE 69120500D1
Authority
DE
Germany
Prior art keywords
alkyl group
substituted alkyl
carbon
aryl
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69120500T
Other languages
English (en)
Other versions
DE69120500T2 (de
Inventor
Koichi Kojima
Hitoshi Kurata
Hiroyoshi Horikoshi
Takakazu Hamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of DE69120500D1 publication Critical patent/DE69120500D1/de
Application granted granted Critical
Publication of DE69120500T2 publication Critical patent/DE69120500T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69120500T 1990-10-29 1991-10-29 Azasteroide zur Behandlung prostatischer Hypertrophie, ihre Herstellung und Verwendung Expired - Fee Related DE69120500T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP29140190 1990-10-29

Publications (2)

Publication Number Publication Date
DE69120500D1 true DE69120500D1 (de) 1996-08-01
DE69120500T2 DE69120500T2 (de) 1997-02-27

Family

ID=17768420

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69120500T Expired - Fee Related DE69120500T2 (de) 1990-10-29 1991-10-29 Azasteroide zur Behandlung prostatischer Hypertrophie, ihre Herstellung und Verwendung

Country Status (19)

Country Link
US (1) US5302621A (de)
EP (1) EP0484094B1 (de)
JP (1) JPH0819151B2 (de)
KR (1) KR0134570B1 (de)
CN (2) CN1053672C (de)
AT (1) ATE139783T1 (de)
AU (1) AU640279B2 (de)
CA (1) CA2054368C (de)
CZ (1) CZ279312B6 (de)
DE (1) DE69120500T2 (de)
DK (1) DK0484094T3 (de)
ES (1) ES2091299T3 (de)
GR (1) GR3020483T3 (de)
HU (2) HU218667B (de)
IE (1) IE76452B1 (de)
IL (1) IL99889A (de)
PT (1) PT99371B (de)
RU (1) RU2070204C1 (de)
ZA (1) ZA918570B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives
CA2084799C (en) * 1991-12-17 2003-01-28 Glenn J. Gormley Method of prevention of prostatic carcinoma with 17 beta-n-monosubstituted-carbamoyl-4-aza-5 alpha-androst-1 -en-3-ones
US5543406A (en) * 1991-12-20 1996-08-06 Glaxo Wellcome, Inc. Inhibitors of 5-α-testosterone reductase
ATE154937T1 (de) * 1992-04-20 1997-07-15 Sankyo Co Steroide zur behandlung von prostatisch- hypertrophe, ihre herstellung und verwendung
US5698720A (en) * 1992-04-20 1997-12-16 Sankyo Company, Limited Steroid derivatives
WO1995012398A1 (en) * 1993-11-04 1995-05-11 Merck & Co., Inc. 7-substituted-4-aza-steroid derivatives as 5-alpha- reductase inhibitors
WO1993023420A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS
CA2135167A1 (en) * 1992-05-20 1993-11-25 Donald W. Graham New 17-ester, amide, and ketone derivatives of 3-oxo-4- azasteroids as 5a-reductase inhibitors
GB9216284D0 (en) * 1992-07-31 1992-09-16 Erba Carlo Spa Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives
GB9216329D0 (en) * 1992-07-31 1992-09-16 Erba Carlo Spa 17beta-substituted 4-aza-5alpha-androstan-3-one derivatives
US5302589A (en) * 1992-08-07 1994-04-12 Glaxo, Inc. Heterocyclic inhibitors of 5-α-testosterone reductase
HU212459B (en) * 1992-10-02 1996-06-28 Richter Gedeon Vegyeszet Process for producing new 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them
WO1994007861A1 (en) * 1992-10-06 1994-04-14 Merck & Co., Inc. 17β-CARBOXANILIDES OF 4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS
WO1994022900A1 (en) * 1993-04-02 1994-10-13 Ciba-Geigy Ag AZA-ANDROSTANE-17β-CARBOXAMIDES
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
US5817818A (en) * 1994-09-16 1998-10-06 Glaxo Wellcome Inc. Androstenones
US5578724A (en) * 1994-09-20 1996-11-26 Eli Lilly And Company Process for preparation of benzo[f]quinolinones
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
IT1271325B (it) * 1994-12-23 1997-05-27 Poli Ind Chimica Spa Composti diastereomericamente puri derivati da 3-oxo e 3-tioxo-4-azaandrostani e loro uso come antiandrogeni
US5656613A (en) * 1995-01-04 1997-08-12 Merck & Co., Inc. Treatment of hyperandrogenic conditions
CN1072679C (zh) * 1995-07-30 2001-10-10 重庆医科大学 一种氮杂甾体化合物、制备及其用途
EP0859761A4 (de) * 1995-09-15 2000-01-26 Merck & Co Inc 4-azasteroide zur behandlung von hyperandrogenen zuständen
US6001844A (en) * 1995-09-15 1999-12-14 Merck & Co., Inc. 4-Azasteroids for treatment of hyperandrogenic conditions
ATE208631T1 (de) * 1996-02-05 2001-11-15 Sankyo Co 5-alpha reductase inhibierende zusammenstellung zur oralen verabreichung, verfahren zur herstellung und deren verwendung
WO1998038207A1 (fr) * 1997-02-26 1998-09-03 Sankyo Company, Limited Compositions de traitement ou de prevention du cancer de la prostate
US6093722A (en) 1997-02-26 2000-07-25 Sankyo Company, Limited Method for treating prostate cancer
BR9811293A (pt) * 1997-07-29 2000-08-29 Sankyo Co Composições para o tratamento da alopecia, do hirsutismo feminino ou da seborréia, ou uma composição para a prevenção da metástase óssea causada por câncer prostático, e, usos de um composto e de n-{1-metil-1-(4-metoxifenil)etil}-3-oxo-4-aza-5-alfa-and rost-1-eno-17-beta-c arboxamida
US6187925B1 (en) * 1997-12-23 2001-02-13 Merck & Co., Inc. Intermediates and process for the synthesis of azasteroids
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
PL372920A1 (en) * 2002-03-13 2005-08-08 Merck & Co,Inc. Fluorinated 4-azasteroid derivatives as androgen receptor modulators
AU2004238238C1 (en) * 2003-05-07 2010-01-14 Merck Sharp & Dohme Corp. Androgen receptor modulators and methods of use thereof
CA2530182A1 (en) * 2003-06-30 2005-01-20 Merck & Co., Inc. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
US7696217B2 (en) * 2003-06-30 2010-04-13 Merck Sharp & Dohme Corp. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
AU2004259664B2 (en) * 2003-06-30 2009-05-28 Merck Sharp & Dohme Corp. 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
EP1734963A4 (de) * 2004-04-02 2008-06-18 Merck & Co Inc Verfahren zur behandlung von menschen mit metabolischen und anthropometrischen störungen
EP2371367A1 (de) * 2005-03-25 2011-10-05 Merck Sharp & Dohme (I.A.) Corp. Verfahren zur Behandlung von Männern mit Testosteronergänzung und Alpha-Reduktase-Hemmer
CN116621913A (zh) * 2022-08-12 2023-08-22 上海醇健实业发展有限公司 一种4-氮杂甾体化合物及其制备方法、用途及药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179453A (en) 1978-04-13 1979-12-18 Merck & Co., Inc. Process for preparing 17β-carboxy-5-androsten-3-ones
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US4220775A (en) * 1979-03-15 1980-09-02 Merck & Co., Inc. Preparation of 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
US5021575A (en) * 1989-11-13 1991-06-04 Merck & Co., Inc. Method for introducing a 1,2 double bond into azasteroids

Also Published As

Publication number Publication date
CA2054368C (en) 2001-10-02
CA2054368A1 (en) 1992-04-30
HK1005456A1 (en) 1999-01-08
HU913396D0 (en) 1992-01-28
HK1017274A1 (en) 1999-11-19
CS326991A3 (en) 1992-05-13
AU8682191A (en) 1992-04-30
IE76452B1 (en) 1997-10-22
PT99371A (pt) 1992-09-30
CZ279312B6 (cs) 1995-04-12
US5302621A (en) 1994-04-12
ATE139783T1 (de) 1996-07-15
HU211642A9 (en) 1995-12-28
DE69120500T2 (de) 1997-02-27
CN1072935C (zh) 2001-10-17
EP0484094A3 (en) 1993-07-14
HUT59417A (en) 1992-05-28
CN1053672C (zh) 2000-06-21
KR0134570B1 (ko) 1998-04-14
RU2070204C1 (ru) 1996-12-10
JPH0532693A (ja) 1993-02-09
CN1062145A (zh) 1992-06-24
KR920008063A (ko) 1992-05-27
AU640279B2 (en) 1993-08-19
EP0484094A2 (de) 1992-05-06
ZA918570B (en) 1992-08-26
HU218667B (hu) 2000-10-28
IL99889A0 (en) 1992-08-18
IE913747A1 (en) 1992-05-22
PT99371B (pt) 1999-04-30
GR3020483T3 (en) 1996-10-31
CN1209319A (zh) 1999-03-03
JPH0819151B2 (ja) 1996-02-28
ES2091299T3 (es) 1996-11-01
EP0484094B1 (de) 1996-06-26
DK0484094T3 (da) 1996-10-28
IL99889A (en) 1995-06-29

Similar Documents

Publication Publication Date Title
DE69120500D1 (de) Azasteroide zur Behandlung prostatischer Hypertrophie, ihre Herstellung und Verwendung
DE69311837D1 (de) Steroide zur Behandlung von Prostatisch-Hypertrophe, ihre Herstellung und Verwendung
ATE89822T1 (de) Durch benzhydryl n-substituierte heterocyclische derivate, ihre herstellung und ihre verwendung.
DE69330949D1 (de) Gaba und l-glutaminsaüre analoga zur behandlung der epilepsie
DE69332577D1 (de) Verfahren zur Herstellung von 13-Ether-Derivaten von Milbemycinen und Zwischenprodukte
ATE138571T1 (de) Verwendung von dioxabicyclo (3.3.0>octane derivaten zur herstellung eines arzneimittels zur hemmung des cholesterinmetabolismus.
DE3874440D1 (de) Zusammensetzung zur herstellung von antithrombotischen medizinischen erzeugnissen.
NO174848C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive substituerte
HUT50337A (en) Process for producing benzoxazine derivatives and pharmaceutical compositions comprising the compounds
FI103887B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten imidatsolyylimetyyli-pyridiinien valmistamiseksi
GR3019711T3 (en) Spiro-indoline-oxazine compounds with photochromatic and photosensitizing characteristics and the process for their preparation
EP0802179A4 (de) Derivate substituierter amidinonaphthylester
HU905000D0 (en) Process for producing compounds suitable for treatment of gastric ulcer
FI912733A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten /(1-aryylipyrrolidin-2-yyli)metyyli/piperatsiinijohdannaisten valmistamiseksi
DE69108587D1 (de) Verfahren und Zwischenprodukte zur Herstellung von optisch aktiven Chromanderivaten.
ATE186907T1 (de) Optisch aktives 1-phenylpyrrolidonderivat und dessen herstellung
ATE100105T1 (de) Physiologisch aktive substanz fa-4283, derivate und ihre herstellung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee